Healing & Tissue-Repair Peptides

N-acetyl-seryl-aspartyl-lysyl-proline — a naturally occurring anti-fibrotic tetrapeptide derived from the N-terminus of thymosin beta-4, regulated by ACE and studied for cardiac, renal, and pulmonary fibrosis.

A modified analog of BPC-157 incorporating alpha-aminoisobutyric acid (Aib) substitutions to enhance proteolytic stability and extend biological half-life while preserving cytoprotective activity.

A stable dipeptide form of glutamine used in clinical nutrition for gut barrier integrity, immune support, and post-surgical recovery — solving glutamine's instability problem.

A counter-regulatory heptapeptide of the renin-angiotensin system that opposes the vasoconstrictive and pro-inflammatory effects of angiotensin II through the Mas receptor, with cardioprotective, anti-fibrotic, and anti-inflammatory properties.

An endogenous peptide ligand for the APJ receptor (apelin receptor) with potent cardiovascular, angiogenic, and fluid homeostasis functions, studied as a potential therapeutic in heart failure and metabolic disease.

A long-acting GLP-2 receptor agonist in late-stage development for short bowel syndrome with intestinal failure, engineered for once-weekly dosing to promote intestinal growth and improve nutrient and fluid absorption.

A 15-amino-acid peptide fragment derived from gastric juice protein BPC, studied extensively in animal models for tissue healing and gut integrity.

A 21-amino-acid endogenous peptide derived from chromogranin A that inhibits catecholamine release via nicotinic acetylcholine receptor antagonism, with cardiovascular protective, antimicrobial, and metabolic regulatory properties under active investigation for hypertension and heart failure.

Calcitonin gene-related peptide, the most potent endogenous vasodilator known, with a central role in migraine pathophysiology and emerging significance in wound healing and cardiovascular protection.

A peripherally-restricted kappa-opioid receptor agonist peptide — approved for the itching (pruritus) of chronic kidney disease in dialysis patients, without the central effects of classic opioids.

A long-acting GLP-2 receptor analog engineered for less-frequent dosing than teduglutide. Investigated for short bowel syndrome, it stimulates intestinal mucosal growth and absorption with a once- or twice-weekly regimen.

A synthetic octapeptide tight junction regulator studied in Phase III clinical trials for celiac disease — acts locally in the gut to prevent paracellular permeability increase (leaky gut).

Linaclotide is an FDA-approved 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist prescribed for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Marketed as Linzess in the US and Constella in Europe, it acts locally in the intestinal lumen to stimulate fluid secretion and reduce visceral pain.

A polyethylene glycol-conjugated variant of BPC-157 engineered for extended half-life and reduced injection frequency while retaining the parent peptide's tissue-healing properties.

A semi-synthetic glycosaminoglycan with anticoagulant and anti-inflammatory properties, FDA-approved for interstitial cystitis and studied for osteoarthritis cartilage protection.

An FDA-approved 16-amino acid guanylate cyclase-C (GC-C) agonist structurally analogous to human uroguanylin, prescribed for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

Synthetic fragment of Thymosin β4 investigated for actin-binding, cell migration, and tissue repair across muscle, cornea, and cardiac models.

An FDA- and EMA-approved GLP-2 analog that promotes intestinal mucosal growth. Used to reduce parenteral nutrition dependence in short bowel syndrome, teduglutide increases villus height, crypt depth, and nutrient absorption.

A 43-amino acid peptide and the primary intracellular G-actin sequestering protein. TB-500 is a synthetic fragment of Thymosin Beta-4's active site — this is the full-length parent molecule with broader tissue repair and anti-inflammatory evidence.

A synthetic cone-snail venom peptide (ω-conotoxin) delivered directly into spinal fluid — an approved non-opioid treatment for severe, refractory chronic pain.